EMMA (Emmaus Life Sciences) Other Long-Term Liabilities: $12.42 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Emmaus Life Sciences Other Long-Term Liabilities?

Emmaus Life Sciences EMMA Other Long-Term Liabilities is $12.42 Mil as of Mar. 2026. The stock has 6 warning signs investors should review.

Emmaus Life Sciences's other long-term liabilities for the quarter that ended in Mar. 2026 was $12.42 Mil.

Emmaus Life Sciences's quarterly other long-term liabilities declined from Sep. 2025 ($12.31 Mil) to Dec. 2025 ($12.29 Mil) but then increased from Dec. 2025 ($12.29 Mil) to Mar. 2026 ($12.42 Mil).

Emmaus Life Sciences's annual other long-term liabilities declined from Dec. 2023 ($17.36 Mil) to Dec. 2024 ($13.47 Mil) and declined from Dec. 2024 ($13.47 Mil) to Dec. 2025 ($12.29 Mil).

Emmaus Life Sciences Other Long-Term Liabilities Related Terms

Emmaus Life Sciences Other Long-Term Liabilities Historical Data

* Premium members only.

The historical data trend for Emmaus Life Sciences's Other Long-Term Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Emmaus Life Sciences Other Long-Term Liabilities Chart

Emmaus Life Sciences Annual Data
Trend Sep16 Sep17 Sep18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Long-Term Liabilities
Get a 7-Day Free Trial Premium Member Only Premium Member Only 23.17 21.71 17.36 13.47 12.29

Emmaus Life Sciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Long-Term Liabilities Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.37 13.13 12.31 12.29 12.42

Emmaus Life Sciences Other Long-Term Liabilities Calculation

Other Long-Term Liabilities are the other liabilities on the balance sheet that do not need to be repaid within the next 12 months, but still need to be repaid over time. For instance, on Wal-Mart's balance sheet, there are items called Long Term obligations under capital leases, deferred income taxes, and redeemable non-controlling interest. These are all Other Long-Term Liabilities.

What does a Other Long-Term Liabilities of $12.42 Mil mean?
Emmaus Life Sciences (EMMA) has a Other Long-Term Liabilities of $12.42 Mil as of Mar. 2026. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Emmaus Life Sciences and its competitors.
Is Emmaus Life Sciences' Other Long-Term Liabilities too high?
Emmaus Life Sciences' current Other Long-Term Liabilities is $12.42 Mil.
How does Emmaus Life Sciences' Other Long-Term Liabilities compare to AGTX and BZYR?
Emmaus Life Sciences' Other Long-Term Liabilities of $12.42 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Long-Term Liabilities for a Biotechnology company?
A good Other Long-Term Liabilities depends on the Biotechnology industry context. However, Other Long-Term Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Long-Term Liabilities mean?
A high Other Long-Term Liabilities can signal that a stock is expensive relative to its fundamentals. Other long-term liabilities as record on a company's balance sheet not categorized as standard liabilities. View historical data on Emmaus Life Sciences and its competitors. Emmaus Life Sciences's current Other Long-Term Liabilities is $12.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Emmaus Life Sciences stock overvalued right now?
Based on GuruFocus' analysis, Emmaus Life Sciences (EMMA) is currently considered Fairly Valued. The stock's GF Value™ is $0.01, compared to a current price of $0.01 — trading right at its estimated fair value. The current Other Long-Term Liabilities is $12.42 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Long-Term Liabilities calculated?
Other Long-Term Liabilities is calculated from a company's financial statements. For Emmaus Life Sciences (EMMA), the current Other Long-Term Liabilities is $12.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Emmaus Life Sciences Business Description

Address 21250 Hawthorne Boulevard, Suite 800, Torrance, CA, USA, 90503
Emmaus Life Sciences Inc is a commercial-stage biopharmaceutical company engaged in the discovery, development, marketing and sales of the Company's product Endari (prescription grade L-glutamine oral powder), to reduce the acute complications of sickle cell disease (SCD) in adult and pediatric patients five years of age and older. Endari is reimbursable by the Centers for Medicare and Medicaid Services, and every state provides coverage for Endari for outpatient prescriptions to all eligible Medicaid enrollees within their state Medicaid programs. Endari is also reimbursable by many commercial payors.